Jae-Joon Kim
Directeur/Membre du Conseil chez YOUCEL, Inc.
Fortune : 459 563 $ au 31/05/2024
Provenance du réseau au premier degré de Jae-Joon Kim
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
Mirae Asset Venture Investment Co., Ltd. /Venture Capital/
 Mirae Asset Venture Investment Co., Ltd. /Venture Capital/ Investment ManagersFinance Mirae Asset Venture Investment Co., Ltd. /Venture Capital/ (Mirae Asset Venture) is a private equity & venture capital subsidiary of Mirae Asset Venture Investment Co., Ltd. founded in 1999. The firm is headquartered in Seongnam, South Korea with an office in Seoul.
37
| Operating Division | Investment Managers | 37 |
ImmunoMet Therapeutics, Inc.
 ImmunoMet Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ImmunoMet Therapeutics, Inc. operates as a development-stage biopharmaceutical company that develops and commercializes novel oncology products. It offers novel technology that designed to disrupt cancer cell growth and enhance anti-cancer immunity. The company was founded in July 2015 and is headquartered in Houston, TX.
6
| Holding Company | Pharmaceuticals: Major | 6 |
YOUCEL, Inc.
 YOUCEL, Inc. BiotechnologyHealth Technology YOUCEL, Inc. engages in the manufacture and sale of cosmetics and pharmaceutical products. Its products include facial masks, cleansers, and hair and skin care products. The company was founded on August 18, 2008 and is headquartered in Iksan-si, South Korea.
3
| Private Company | Biotechnology | 3 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Jae-Joon Kim via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
| PFIZER, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| ASTRAZENECA PLC | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| REPROS THERAPEUTICS INC | Pharmaceuticals: Major | President | |
Carnegie Mellon University
 Carnegie Mellon University Other Consumer ServicesConsumer Services Carnegie Mellon University is an American school that operates as a college or university. It is located in Pittsburgh, Pennsylvania. | College/University | Masters Business Admin | |
| SYNDAX PHARMACEUTICALS, INC. | Biotechnology | Chief Executive Officer | |
| MILESTONE PHARMACEUTICALS INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
MPM BioImpact, Inc
 MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Private Equity Investor | |
| HANALL BIOPHARMA CO., LTD. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
| DAEWOONG PHARMACEUTICAL CO., LTD | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Fenwick & West LLP
 Fenwick & West LLP Miscellaneous Commercial ServicesCommercial Services Fenwick & West LLP provides legal services to technology and life sciences clients. Its practice areas include antitrust and unfair competition, appellate, complex business litigation, copyright, corporate and securities, employment and labor, executive compensation and benefits, intellectual property, and IP litigation. The firm offers legal advisory services in areas such as mergers and acquisitions, patent prosecution, privacy and information security. The company was founded in 1972 and is headquartered in Mountain View, CA. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| University of Illinois | College/University | Doctorate Degree | |
| Georgetown University | College/University | Undergraduate Degree | |
| The State University of New York | College/University | Graduate Degree | |
EMD Serono, Inc.
 EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| Yonsei University | College/University | Undergraduate Degree Graduate Degree | |
| INCON CO.,LTD. | Electronics/Appliances | Director/Board Member | |
| Seoul National University | College/University | Undergraduate Degree Undergraduate Degree | |
| Radboud University Nijmegen | College/University | Doctorate Degree | |
Mirae Asset Capital Co., Ltd.
 Mirae Asset Capital Co., Ltd. Investment ManagersFinance Mirae Asset Capital Co., Ltd. (Mirae Asset Capital) is a private equity and venture capital firm founded in 1997. The firm is headquartered in Seoul, South Korea. | Investment Managers | Director/Board Member | |
| Hanyang University | College/University | Graduate Degree Graduate Degree | |
| Cheongju University | College/University | Undergraduate Degree | |
Mirae Asset Securities Co., Ltd. (Broker)
 Mirae Asset Securities Co., Ltd. (Broker) Investment Banks/BrokersFinance Mirae Asset Securities Co., Ltd. (Broker) (Mirae Asset-Broker) is the broker/dealer division of Mirae Asset Securities Co., Ltd. (KRX: 006800), a publicly-listed investment banking and stock brokerage company headquartered in Seoul, South Korea. Founded in 1902, Mirae Asset-Broker originates, structures, and executes a series of products and solutions linked to equity, derivatives, commodities, options, fixed-income, currency, and alternative investment products and provides them to financial institutions and wealth management organizations in Korea and overseas. | Investment Banks/Brokers | Analyst-Equity | |
| Korea University | College/University | Undergraduate Degree | |
| HYULIM A-TECH CO., LTD. | Textiles | Director/Board Member | |
Neomics Co., Ltd.
 Neomics Co., Ltd. Pharmaceuticals: MajorHealth Technology Neomics Co., Ltd. develops and commercializes diagnostics and therapeutics for human incurable diseases, such as cancer. It provides services of custom antibody and protein production and offers antibody groups including in-house antibodies from aminoacyl-tRNA synthesize. The company was founded by Chi Uk In in 2005 and is headquartered in Seoul, South Korea. | Pharmaceuticals: Major | Director/Board Member | |
Kyung Hee University
 Kyung Hee University Other Consumer ServicesConsumer Services Kyung Hee University provides academic courses and grants academic degrees. It has udergraduate, graduate, international student, and international faculty programs. The firm also provides scholarships and operates Kyung Hee Medical Center, Kyung Hee University Hospital at Gangdong, and Kangnam Korean Hospital. The company was founded on February 15, 1949 and is headquartered in Seoul, South Korea. | College/University | Corporate Officer/Principal | |
Rutter Associates Korea
 Rutter Associates Korea Investment ManagersFinance Rutter Associates Korea (Rutter PE) is an independent private equity firm headquartered in Seoul, Korea. The firm is established in 2004. | Investment Managers | Private Equity Analyst | |
EQ Partners Co., Ltd.
 EQ Partners Co., Ltd. Investment ManagersFinance EQ Partners Co., Ltd. (Ecu Partners) is a private equity subsidiary of Korea Investment Holdings Co. headquartered in Seoul, South Korea. The firm was founded in 2010. | Investment Managers | Private Equity Investor | |
| UTI INC. | Industrial Specialties | Director/Board Member | |
| NHN CORPORATION | Internet Software/Services | Director/Board Member | |
Transcelerate Biopharma, Inc.
 Transcelerate Biopharma, Inc. BiotechnologyHealth Technology Transcelerate Biopharma, Inc. is a non-profit consortium that collaborates with pharmaceutical and biotechnology companies to improve the delivery of new medicines. The non-profit company is based in King of Prussia, PA. The organization's mission is to identify, prioritize, design, and facilitate implementation of solutions to drive the efficient, effective, and high-quality delivery of new medicines. Transcelerate has 20 member companies and 30+ initiatives focused on improving the patient and site experience, enhancing sponsor efficiencies and drug safety, and harmonizing processes and sharing information. The company was founded by Garry Arthur Neil, and Janice Chang has been the CEO of the company since 2014. | Biotechnology | Chairman | |
| Korean Drug Research Association | Director/Board Member | ||
Health Prime International LLC
 Health Prime International LLC Miscellaneous Commercial ServicesCommercial Services Health Prime International LLC engages in the supply of outsourced medical billing services. It offers PrimeEHR, PrimeQuality, PrimeTranscription, PrimeContact, PrimeConsult, PrimeSmartCharge, and PrimeMarketing. The company was founded by Vinod K. Shah in 2004 and is headquartered in National Harbor, MD. | Miscellaneous Commercial Services | Chief Executive Officer | |
Midas Dong-a Investment Co., Ltd.
 Midas Dong-a Investment Co., Ltd. Investment ManagersFinance Midas Dong-A Investment Co Ltd (Midas Dong-A) is a venture capital firm headquartered in Seoul, Korea. The firm is established in 2013 by Midas Dong-A Co Ltd for its investment activities. | Investment Managers | Private Equity Investor | |
Atrin Pharmaceuticals LLC
 Atrin Pharmaceuticals LLC BiotechnologyHealth Technology Atrin Pharmaceuticals LLC engages in discovery and development of proprietary medications. It offers ATRN-502, a p53 activator; and ATRN-507, a dual ligand showing specificity and selectivity against cancer cells. The firm also provides Atrize, a platform that offers phenotypic FACS-based screening that is applicable across R&D, clinical applications, and a tool for personalized medicine. The company was founded by Oren Gilad and Kevin D. Smith in 2011 and is headquartered in Doylestown, PA. | Biotechnology | Director/Board Member | |
| BRIDGE BIOTHERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Triumvira Immunologics, Inc.
 Triumvira Immunologics, Inc. Pharmaceuticals: MajorHealth Technology Triumvira Immunologics, Inc. develops and manufactures pharmaceutical products. The company was founded by Jonathan Bramson in 2015 and is headquartered in Hamilton, Canada. | Pharmaceuticals: Major | Chief Executive Officer | |
Alliance for Clinical Research Excellence & Safety
 Alliance for Clinical Research Excellence & Safety Miscellaneous Commercial ServicesCommercial Services Alliance for Clinical Research Excellence & Safety is a non-governmental organization that builds, implements, and maintains comprehensive systems. The non-profit company is based in Cambridge, MA. The company was founded by Greg Koski. | Miscellaneous Commercial Services | Director/Board Member | |
| BIO-SYNECTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
| RP BIO INC. | Pharmaceuticals: Major | Chief Executive Officer | |
Auron Therapeutics, Inc.
 Auron Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Auron Therapeutics, Inc. operates as a biotechnology company. It aims to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells. The company was founded by Kate Yen, Matt Vander Heiden, Ross Levine, and Eytan Stein and is headquartered in Wellesley, MA. | Miscellaneous Commercial Services | Chairman | |
| MIRAE ASSET VENTURE INVESTMENT CO., LTD. | Investment Managers | Chief Executive Officer | |
| SALARIUS PHARMACEUTICALS, INC. | Biotechnology | Director/Board Member | |
Bioimpact Capital LLC
 Bioimpact Capital LLC Investment ManagersFinance MPM BioImpact LLC (MPM BioImpact) is a venture capital firm a subsidiary of MPM Bioimpact Inc founded in 1996. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Private Equity Investor | |
Crossbow Therapeutics, Inc.
 Crossbow Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Crossbow Therapeutics, Inc. is a biotechnology company that aims to improve the lives of people with cancer by developing next-generation immunotherapies. The company is based in Cambridge, MA, and the CEO of the company is Briggs W. Morrison. The company's T-bolt™ therapies are designed to target previously unreachable cancer cell targets with high precision. Crossbow's approach is efficient and selective, allowing them to target the entire universe of cancer proteins, which expands the potential of antibody therapy to address many types of cancer. | Pharmaceuticals: Major | Chief Executive Officer | |
| CARISMA THERAPEUTICS, INC. | Biotechnology | Director/Board Member |
Statistiques
Internationale
| Corée du Sud | 26 |
| Etats-Unis | 22 |
| Canada | 3 |
| Royaume-Uni | 2 |
| Pays-Bas | 2 |
Sectorielle
| Health Technology | 19 |
| Consumer Services | 12 |
| Finance | 10 |
| Commercial Services | 7 |
| Process Industries | 4 |
Opérationnelle
| Director/Board Member | 40 |
| Private Equity Investor | 27 |
| Chief Executive Officer | 13 |
| Private Equity Analyst | 12 |
| Independent Dir/Board Member | 11 |
Relations les plus connectées
| Insiders | |
|---|---|
| Briggs Morrison | 26 |
| Bong-Yong Lee | 9 |
| Paul Lammers | 7 |
| Nam-Ki Kim | 6 |
| Sung-Wuk Kim | 6 |
| Benjamin R. Cowen | 6 |
| Eung-Suk Kim | 4 |
| Jung-Hoon Chae | 3 |
| Brian Oh | 3 |
| Jeong-Soo Han | 3 |
| Gyu-Seung Shin | 3 |
| Jae-Woo Kim | 2 |
| Chan-Oh Park | 2 |
| Dong-Hee Hong | 2 |
| Justin Kim | 1 |
- Bourse
- Insiders
- Jae-Joon Kim
- Connexions Sociétés
